The ongoing controversy over experimental strains of bird flu is one of those multi-dimensional stories that you just can’t fit into one article. I’ve written about it at Slate and here at the Loom, and I can point elsewhere to no end of excellent stuff. Fellow Discover blogger Ed Yong has a sharp, concise round-up on the research over at Nature, for example, and Michael Specter has a new story on it in this week’s New Yorker (subscription required, alas).

In tomorrow’s New York Times, I take a look into one dimension of the story that has seemed under-explored to me. The controversy over the bird flu revolves around the risk that publishing the full details of the